Active	Status	Sponsor type	Region	Phase	Filter
8 Active 9 Inactive 17 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

8 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
pemvidutide (ALT-801) / Altimmune
MOMENTUM, NCT05295875: Efficacy and Safety of ALT-801 in the Treatment of Obesity	Completed	2	391	US	ALT-801, Placebo	Altimmune, Inc.	Obesity/Overweight	09/23	09/23
IMPACT, NCT05989711: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH) ( Trial)	Recruiting	2	190	US, RoW	Pemvidutide, Placebo	Altimmune, Inc.	Non-Alcoholic Steatohepatitis (NASH)	02/25	09/25
NCT05006885: ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)	Completed	1	95	US	ALT-801, Pemvidutide, Placebo	Altimmune, Inc.	Non-Alcoholic Fatty Liver Disease	08/22	08/22
NCT05292911: Extension of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With (NAFLD)	Completed	1	64	US	ALT-801, Pemvidutide, Placebo	Altimmune, Inc.	Non-Alcoholic Fatty Liver Disease	10/22	10/22
NCT05134662: ALT-801 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus (T2DM)	Completed	1	55	US	ALT-801, Placebo	Altimmune, Inc.	Type 2 Diabetes	02/23	03/23
AdCOVID (COVID-19 vaccine) / Altimmune, The University of Alabama
NCT04679909: Safety and Immunogenicity of AdCOVID in Healthy Adults (COVID-19 Vaccine Study)	Completed	1	92	US	AdCOVID, Placebo	Altimmune, Inc.	Healthy Volunteers	12/21	12/22
HepTcell (FP-02.2) / Altimmune
2020-002118-42: Phase 2, double-blind, randomized, placebo-controlled study of HepTcell as a vaccine in treatment of patients with inactive chronic hepatitis B	Not yet recruiting	2	80	Europe, RoW	HepTcell (Adjuvanted FP-02.2), IC31 Adjuvant, IC31, Lyophilisate for suspension for injection, Solution for injection	Altimmune, Inc., Altimmune, Inc	Inactive Chronic Hepatitis B (CHB), Inactive Chronic Hepatitis B (CHB), Diseases [C] - Virus Diseases [C02]
NCT04684914: HepTcell Immunotherapy in Patients With Inactive Chronic Hepatitis B (CHB)	Terminated	2	87	Europe, Canada, US	HepTcell, Placebo	Altimmune, Inc.	Hepatitis B, Chronic	03/24	04/24